07:00 , Sep 3, 2012 |  BioCentury  |  Strategy

Back to School: Science & austerity

We have entered an age of austerity that, given the fecklessness of the political classes, won't end any time soon. Against that backdrop, the global science community must decide how to succeed with less money. Major...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Clinical News

IMGN901: Phase I/II data

Pooled data from 68 evaluable small cell lung cancer (SCLC) patients in the Phase I Study 002 trial and the Phase I/II Study 001 trial showed that IMGN901 produced 1 PR, 1 unconfirmed PR and...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Clinical News

Enkam preclinical data

In a rat model of chronic stress-induced cognitive deficits, FGL prevented long-term cognitive side effects. Data will be published in Behavioural Pharmacology. A Phase I trial of the neural cell adhesion molecule (NCAM) mimicking...
07:00 , Aug 13, 2007 |  BioCentury  |  Tools & Techniques

Expanding the liver repertoire

Researchers from the University of North Carolina at Chapel Hill reported in the Journal of Experimental Medicine the identification and successful expansion of human hepatic stem cells, a discovery that could speed the development of...
08:00 , Jan 8, 2007 |  BioCentury  |  Emerging Company Profile

Pharmaxon: Normalizing neurons

Based on the fact that several CNS indications are characterized at least in part by abnormal movement of neurons, Pharmaxon S.A. is developing adhesion molecule modulators to normalize or re-establish normal neuronal connections for spinal...
07:00 , Sep 11, 2006 |  BC Week In Review  |  Clinical News

Enkam preclinical data

In vitro data showed that C3d, a neural cell adhesion molecule (NCAM) derived peptide, inhibited interleuekin 1 beta-induced MAP kinase activity and beta cell apoptosis. Data were published in Diabetologia. Enkam Pharmaceuticals A/S, Copenhagen,...
07:00 , Sep 11, 2006 |  BioCentury  |  Tools & Techniques

Blocking beta cell destruction

Neural cell adhesion molecule (NCAM), a glycoprotein that is expressed in all nerve cells and has a role in their health, growth and communication, may also be a potential therapeutic target for Type I diabetes....
07:00 , Jul 17, 2006 |  BC Week In Review  |  Clinical News

Enkam preclinical data

In a mouse model of brain injury, subcutaneous Plannexin reduced oxidative stress, neurodegeneration and apoptosis. The neural cell adhesion molecule (NCAM) agonist also induced neuroprotection. Data were presented at the European Neuroscience meeting in...
07:00 , Jul 17, 2006 |  BC Week In Review  |  Clinical News

Enkam preclinical data

In a mouse model of traumatic brain injury, Dennexin reduced the number of macrophages, which inhibited the inflammatory response and reduced the degree of inflammation. The neural cell adhesion molecule (NCAM) agonist significantly increased...
07:00 , May 23, 2005 |  BC Week In Review  |  Clinical News

FGLL: Phase I data

Data from a Phase I trial in 24 healthy volunteers receiving intranasal administration showed 1 of 3 doses of FGLL was safe and well tolerated. Enkam Pharmaceuticals A/S, Copenhagen, Denmark   Product: FGLL   Business: Neurology   Molecular...